COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

30,999 Articles (22,627 medRxiv, 8,372 bioRxiv)

Most recent first Previous |  Page 908: Articles 9071-9080  | Next

Lyophilized mRNA-lipid nanoparticles vaccine with long-term stability and high antigenicity against SARS-CoV-2
Ai, L., Li, Y., Zhou, L., Zhang, H., Yao, W., Han, J., Wu, J., Wang, R., Wang, W., Xu, P., Li, Z., Wei, C., Chen, H., Liang, J., Guo, M., Huang, Z., Wang, X., Zhang, Z., Xiang, W., Lv, B., Peng, P., Zhang, S., Ji, X., Li, Z., Luo, H., Chen, J., Lan, K., Hu, Y.
10.1101/2022.02.10.479867 — Posted: 2022-02-10
Predicting Epitope Candidates for SARS-CoV-2
Agarwal, A., Beck, K. L., Capponi, S., Kunitomi, M., Nayar, G., Seabolt, E., Mahadeshwar, G., Bianco, S., Mukherjee, V., Kaufman, J.
10.1101/2022.02.09.479786 — Posted: 2022-02-10
Engineering Defensin α-helix to produce high-affinity SARS-CoV-2 Spike protein binding ligands.
Fernandes, L. A., Gomes, A. A., Magalhaes, M. d. L. B., Ray, P., da Silva, G. F.
10.1101/2022.02.09.479781 — Posted: 2022-02-10
Distinct Core Glycan and O-Glycoform Utilization of SARS-CoV-2 Omicron Variant Spike Protein RBD Revealed by Top-Down Mass Spectrometry
Roberts, D. S., Mann, M., Li, B. H., Kim, D., Brasier, A. R., Jin, S., Ge, Y.
10.1101/2022.02.09.479776 — Posted: 2022-02-10
The REinfection in COVID-19 Estimation of Risk (RECOVER) study: Reinfection and serology dynamics in a cohort of Canadian healthcare workers.
Racine, E., Boivin, G., Longtin, Y., McCormack, D., Decaluwe, H., Savard, P., Cheng, M. P., Hamelin, M.-E., Tadount, F., Adams, K., Bourdin, B., Nantel, S., Gilca, V., Corbeil, J., De Serres, G., Quach, C.
10.1101/2022.02.10.22269967 — Posted: 2022-02-10
COVID Testing in the Workplace: Return to Work Testing in an Occupational Cohort
Sikka, R., Wyllie, A. L., Premsirut, P., Berke, E.
10.1101/2022.02.09.22270653 — Posted: 2022-02-10
Cov2MS: an automated matrix-independent assay for mass spectrometric detection and measurement of SARS-CoV-2 nucleocapsid protein in infectious patients
Van Puyvelde, B., Van Uytfanghe, K., Van Oudenhove, L., Gabriels, R., Van Royen, T., Matthys, A., Razavi, M., Yip, R., Pearson, T., Van Hulle, M., Claereboudt, J., Wyndham, K., Jones, D., Saelens, X., Martens, G. A., Stove, C., Deforce, D., Martens, L., Vissers, H. P. C., Anderson, N. L., Dhaenens, M.
10.1101/2022.02.09.22270547 — Posted: 2022-02-10
The COVID-19 Community Research Partnership: Objectives, Study Design, Baseline Recruitment, and Retention
The COVID-19 Community Research Partnership Study Group, , Sanders, J.
10.1101/2022.02.09.22270272 — Posted: 2022-02-10
Machine Learning Generalizability Across Healthcare Settings: Insights from multi-site COVID-19 screening
Yang, J., Soltan, A. A., Clifton, D. A.
10.1101/2022.02.09.22269744 — Posted: 2022-02-10
Implementation and economic effects of local non-pharmaceutical interventions
Godoy, A. A., Grotting, M. W.
10.1101/2022.02.10.22270783 — Posted: 2022-02-10

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).